Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer

Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer

Background Tamoxifen, a selective estrogen receptor modulator, is indicated for breast cancer developed in response to estrogen. Findings In the current study we explored the relationship between the different variants of CYP2D6 , CYP2C19 , CYP3A5 and plasma Endoxifen levels in Algerian patients wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Egyptian Journal of Medical Human Genetics 2022-08, Vol.23 (1), p.1-11, Article 122
Hauptverfasser: Boucenna, Amira, Boudaoud, Khadidja, Hireche, Ahmed, Rezgoune, Mohamed Larbi, Abadi, Noureddine, Filali, Taha, Satta, Dalila
Format: Artikel
Sprache:eng
Schlagworte:
Alleles
Breast cancer
CYP2D6
CYP2D6 protein
Cytochrome P450
Endoxifen
Estrogen receptors
Estrogens
Genotyping
Medicine
Medicine & Public Health
Patients
Pharmacogenetics
Plasma levels
Tamoxifen
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Tamoxifen, a selective estrogen receptor modulator, is indicated for breast cancer developed in response to estrogen. Findings In the current study we explored the relationship between the different variants of CYP2D6 , CYP2C19 , CYP3A5 and plasma Endoxifen levels in Algerian patients with ER + breast cancer. We further conducted the relationship between the candidate genes and the recurrences rate. Endoxifen levels differed significantly ( p  
ISSN:2090-2441
1110-8630
2090-2441
DOI:10.1186/s43042-022-00332-7